Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Niraparib
Related studies linked through entity extraction aliases.
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study Evaluating Safety, Tolerability, and Metabolism of Niraparib
- Status
- RECRUITING
- Phase
- PHASE4
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Combination Therapy in Cancers With Mutations in DNA Repair Genes
- Status
- RECRUITING
- Phase
- PHASE1
Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation
- Status
- TERMINATED
- Phase
- PHASE2
Niraparib In Recurrent IDH 1/2 Gliomas
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- EARLY_PHASE1
Niraparib in Tumors Metastatic to the CNS
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers
- Status
- TERMINATED
- Phase
- PHASE1
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
- Status
- RECRUITING
- Phase
- PHASE2
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1